Di Yan

Di Yan

Auto-generated profile, based on publicly available information

Di Yan

Technical University of Munich

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2024
Verified
Conference Paper
Closed access
YCYamei Chen
Yamei Chen
YDYan Di
Yan Di
GZGuangyao Zhai
Guangyao Zhai
FMFabian Manhardt
Fabian Manhardt
CZChenyangguang Zhang
Chenyangguang Zhang
BBBenjamin Busam
Benjamin Busam
Category-level object pose estimation, aiming to predict the 6D pose and 3D size of objects from known categories, typically struggles with large intra-class shape variation. Existing works utilizing mean shapes often fall short of cap-turing this variation. To address this issue, we present Sec-ondPose, a novel approach integrating object-specific ge-ometric features with semantic category priors from DI-NOv2. Leveraging the advantage of DINOv2 in providing SE(3)-consistent semantic features, we hierarchically extract two types of SE(3)-invariant geometric features to further encapsulate local-to-global object-specific information. These geometric features are then point-aligned with DINOv2 features to establish a consistent object represen-tation under SE(3) transformations, facilitating the map-ping from camera space to the pre-defined canonical space, thus further enhancing pose estimation. Extensive exper-iments on NOCS-REAL275 demonstrate that SecondPose achieves a 12.4% leap forward over the state-of-the-art. Moreover, on a more complex dataset HouseCat6D which provides photometrically challenging objects, SecondPose still surpasses other competitors by a large margin.

10 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DKDaniel J. Krauss
Daniel J. Krauss
TKTheodore Karrison
Theodore Karrison
AMAlvaro A. Martinez
Alvaro A. Martinez
GMGerard Morton
Gerard Morton
DYDi Yan
Di Yan
HSHoward M. Sandler
Howard M. Sandler
PURPOSE: It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).METHODS: The NRG Oncology/Radiation Therapy Oncology Group 0815 study randomly assigned 1,492 patients with stage T2b-T2c, Gleason score 7, or prostate-specific antigen (PSA) value >10 and ≤20 ng/mL to dose-escalated RT alone (arm 1) or with STAD (arm 2). STAD was 6 months of luteinizing hormone–releasing hormone agonist/antagonist therapy plus antiandrogen. RT modalities were external-beam RT alone to 79.2 Gy or external beam (45 Gy) with brachytherapy boost. The primary end point was overall survival (OS). Secondary end points included prostate cancer–specific mortality (PCSM), non-PCSM, distant metastases (DMs), PSA failure, and rates of salvage therapy.RESULTS: Median follow-up was 6.3 years. Two hundred nineteen deaths occurred, 119 in arm 1 and 100 in arm 2. Five-year OS estimates were 90% versus 91%, respectively (hazard ratio [HR], 0.85; 95% CI, 0.65 to 1.11]; P = .22). STAD resulted in reduced PSA failure (HR, 0.52; P <.001), DM (HR, 0.25; P <.001), PCSM (HR, 0.10; P = .007), and salvage therapy use (HR, 0.62; P = .025). Other-cause deaths were not significantly different ( P = .56). Acute grade ≥3 adverse events (AEs) occurred in 2% of patients in arm 1 and in 12% for arm 2 ( P <.001). Cumulative incidence of late grade ≥3 AEs was 14% in arm 1 and 15% in arm 2 ( P = .29).CONCLUSION: STAD did not improve OS rates for men with IRPC treated with dose-escalated RT. Improvements in metastases rates, prostate cancer deaths, and PSA failures should be weighed against the risk of adverse events and the impact of STAD on quality of life.

1 June 2023
Verified
Conference Paper
Open access
DZDekai Zhu
Dekai Zhu
GZGuangyao Zhai
Guangyao Zhai
YDYan Di
Yan Di
FMFabian Manhardt
Fabian Manhardt
HBHendrik Berkemeyer
Hendrik Berkemeyer
BBBenjamin Busam
Benjamin Busam
Reliable multi-agent trajectory prediction is crucial for the safe planning and control of autonomous systems. Compared with single-agent cases, the major challenge in simultaneously processing multiple agents lies in modeling complex social interactions caused by various driving intentions and road conditions. Previous methods typically leverage graph-based message propagation or attention mechanism to encapsulate such interactions in the format of marginal probabilistic distributions. However, it is inherently sub-optimal. In this paper, we propose IPCC-TP, a novel relevance-aware module based on Incremental Pearson Correlation Coefficient to improve multi-agent interaction modeling. IPCC-TP learns pairwise joint Gaussian Distributions through the tightly-coupled estimation of the means and covariances according to interactive incremental movements. Our module can be conveniently embedded into existing multi-agent prediction methods to extend original motion distribution decoders. Extensive experiments on nuScenes and Argoverse 2 datasets demonstrate that IPCC-TP improves the performance of baselines by a large margin.

10 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBenjamin Movsas
Benjamin Movsas
JRJoseph P. Rodgers
Joseph P. Rodgers
MEMohamed A. Elshaikh
Mohamed A. Elshaikh
AMAlvaro A. Martinez
Alvaro A. Martinez
GMGerard C. Morton
Gerard C. Morton
DBDeborah W. Bruner
Deborah W. Bruner
PURPOSE: To report patient-reported outcomes (PROs) of a phase III trial evaluating total androgen suppression (TAS) combined with dose-escalated radiation therapy (RT) for patients with intermediate-risk prostate cancer.METHODS: Patients with intermediate-risk prostate cancer were randomly assigned to dose-escalated RT alone (arm 1) or RT plus TAS (arm 2) consisting of luteinizing hormone-releasing hormone agonist/antagonist with oral antiandrogen for 6 months. The primary PRO was the validated Expanded Prostate Cancer Index Composite (EPIC-50). Secondary PROs included Patient-Reported Outcome Measurement Information System (PROMIS)-fatigue and EuroQOL five-dimensions scale questionnaire (EQ-5D). PRO change scores, calculated for each patient as the follow-up score minus baseline score (at the end of RT and at 6, 12, and 60 months), were compared between treatment arms using a two-sample t test. An effect size of 0.50 standard deviation was considered clinically meaningful.RESULTS: For the primary PRO instrument (EPIC), the completion rates were ≥86% through the first year of follow-up and 70%-75% at 5 years. For the EPIC hormonal and sexual domains, there were clinically meaningful ( P < .0001) deficits in the RT + TAS arm. However, there were no clinically meaningful differences by 1 year between arms. There were also no clinically meaningful differences at any time points between arms for PROMIS-fatigue, EQ-5D, and EPIC bowel/urinary scores.CONCLUSION: Compared with dose-escalated RT alone, adding TAS demonstrated clinically meaningful declines only in EPIC hormonal and sexual domains. However, even these PRO differences were transient, and there were no clinically meaningful differences between arms by 1 year.

1 January 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DYDi Yan
Di Yan
SCShupeng Chen
Shupeng Chen
DKDaniel J. Krauss
Daniel J. Krauss
RDRohan Deraniyagala
Rohan Deraniyagala
PCPeter Chen
Peter Chen
GWGeorge Wilson
George Wilson

1 October 2005 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
PDF file
YHY. Hasan
Y. Hasan
LKL. Kim
L. Kim
DWD. Weed
D. Weed
LKL. Kestin
L. Kestin
AMA. Martinez
A. Martinez
DYD. Yan
D. Yan